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Clinical Features and Outcome of Surgery in 30 Patients with Acromegaly
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Endocrinology Section, Department of Medicine, Aga Khan University Hospital, Karachi.

Abstract
Objective: To assess the surgical outcome of hypophysectomy in acromegalic patients, differences in response
to surgery in micro and macroadenoma and the development of associated hormonal deficiency after surgery.
Methods: Retrospective analysis of charts of acromegalic patients who were operated upon at Aga Khan
University Hospital, Karachi, was done. Information regarding presentation, laboratory data, radiological assessment, details of surgery and postoperative outcome was recorded. Surgical outcome was classified depending
on the degree of disease control after surgery as biochemical cure, remission and treatment failure.
Results: Out of 30 patients, eighteen (60%) were males and 12 (40%) females with mean age at the time of
diagnosis 35.6± 10.4 years. The mean duration of symptoms was 3.2± 2.4 years. Twenty-five patients had
macroadenoma and five had microadenoma. Preoperative mean GH level was 42.4ng/ml with range of 2.5 to
534 ng/ml. Following surgery, 13 had biochemical cure, 4 were in remission and 13 failed to respond. The outcome in microadenoma was better than in macroadenoma i.e. 100% vs. 32%. Preoperatively four patients had
panhypopituitarism with additional six patients(20%) developing hypopituitarism postoperatively.
Conclusion: Our study showed that acromegaly was seen at a much earlier age, outcome of surgery was comparable to other international studies and postoperative panhypopituitarism was seen in significant number of
patients. The outcome in microadenoma was better than in macroadenoma but the number of patients seen with
microadenoma was small (JPMA 54:315;2004).

Introduction
Acromegaly is an uncommon disease with an annual incidence of 3/million and an estimated prevalence of
40/million population.1 In the majority of patients it is
caused by a pituitary adenoma and is associated with significantly shortened life span that is not due to direct effect
from the tumour but results from cardiovascular, respiratory and cerebrovascular complications.2 In addition there is
an increased risk of malignancy.3 Acral growth, coarsened
facial features and soft tissue swelling are the most common
symptoms of acromegaly4 which develop slowly over time
so the diagnosis is delayed for years.5
Optimal therapy should be aimed at alleviating
symptoms, reducing tumour bulk, preventing regrowth and
reducing mortality without the development of hypopitu-

itarism.6 Surgery remains the treatment of choice as this
offers a rapid permanent reduction of Growth hormone
(GH) level and relief from the mass effect of the tumour. In
those patients in whom operative cure is not achieved,
radiotherapy and/or medical therapy are useful treatment
modalities. Biochemical cure is considered as GH level<2.5
ng/ml, normal IGF level and post Oral Glucose Tolerance
Test(OGTT), GH level<1 ng/ml.7,8 Using strict criteria for
cure, rate as high as 67% have been reported for surgery
alone.9 Outcome of surgery is inversely correlated to preoperative GH level10, tumour size11 and tumour stage.12
We retrospectively analyzed the medical records of
patients with acromegaly who were operated upon, to asses
the surgical outcome of hypophysectomy, the difference

in outcome of microadenoma and macroadenoma and
development of postoperative hormonal deficiencies.

Patients and Methods
A retrospective review of medical records was performed on 45 patients with the diagnosis of Acromegaly
who presented at Aga Khan University Hospital between
1989-2002.
Ten patients who had had previous pituitary surgery
or irradiation were excluded. Five patients who did not
undergo surgery were also excluded.Information regarding
presentation, investigations like hormonal and radiological
assessment, details of surgery and postoperative outcome
were recorded.
All patients exhibited signs and symptoms of
acromegaly with confirmation of diagnosis by elevated
baseline GH levels and OGTT suppression test. An Oral
Glucose Tolerance Test was performed by fasting the patient
overnight and then taking a 0900 h basal blood sample. The
patient was then given an oral dose of 75 g of glucose.
Blood samples were collected every 30 min for 120 min and
were analyzed for GH and glucose levels.

Statistical package for social science SPSS (Release 10.0.5,
standard version, copyright © SPSS; 1989-99) was used for
data analysis.

Results
Patient population
Out of 30 patients, eighteen were males (60%) and
12 were females (40%). The mean age of patients at the time
of diagnosis was 35.6 ± 10.4 years (range, 16-52) (Figure
1). The mean duration of symptoms reported by the patient
at the time of diagnosis was 3.2 ± 2.4 years.
The majority of tumours were macroadenoma, i.e.
25 patients (83%) but 5 had microadenoma (17%). Out of
25 macroadenamas, 19 had suprasellar extension and 12
were with optic chiasmal compression. Cavernous sinus
involvement was present in 3 patients and sellar floor
destruction with sphenoid sinus involvement in 3 patients.
Preoperative mean GH level was 42.4ng/ml with

Preoperative MRI/CT scan were done and tumours
were classified into macro (>10 mm) or microadenomas
(<10 mm).
The postoperative cure was assessed by measuring
random GH levels in most of the patients and postoperative
OGTT suppression test was done in five patients. The hormonal assessment was done within two weeks of surgery.
Biochemical cure was considered to be achieved when there
was suppression of random GH level of <2.5 ng/ml or
serum GH <1 ng/ml after OGTT, remission when GH level
was between 2.5 and 5.0 ng/ml and failure to surgical treatment when persistently elevated random GH levels or failure to suppress/paradoxical rise of GH on OGTT.7,13
Postoperative workup also included repeat MRI scan
of pituitary and hormonal assessment for pituitary insufficiency. GH measurement was done using Immulite® 2000
analyzer(Diagnostic Product Corp. Ltd.) with chemilumminescence assay. The normal adult range for this kit was
0.06-5.0 ng/ml.

Figure 1. Age distribution.

Table 1. Summary of characteristics of adenomas.
Characteristics

MRI size of adenoma
Macro

Micro

(n=25)

(n=5)

p-value

Pre-op GH level

30.4 (5.8-534)

12.5 (5.3-19)

0.015

Post-op GH level

5.7 (0.5-213)

0.9 (0.4-1.9)

0.021

Age (years)

31 (16-52)

45 (37-51)

0.016

2 (0.5-10)

5 (0.3-9)

0.552

Statistical Method

Duration of

Results were expressed as mean + standard deviation, median with range for all continuous variables (e.g,
age, duration of symptoms etc.) and number (percentage)
for categorical data (e.g, gender, surgical outcome etc.).
Univariate analysis was performed by using the Pearson
Chi-square test, Fisher Exact test, and Mann Whitney U-test
whenever appropriate. A p-value <0.05 was considered as
statistically significant. All p-value were two sided. The

symptoms (years)

range of 2.5 to 534 ng/ml. In patients with microadenoma
GH level was between 4.5 - 17.5ng/ml whereas higher levels were seen with macroadenoma. Preoperative OGTT suppression was done in 10 patients and was found to be abnormal in all.

Table 2. Surgical outcome.
Outcome of surgery
Cure
Pre-op MRI

Macro

8 (32%)

size of adenoma

Micro

5 (100%)

Total

13 (43.3%)

Figure 2. GH levels in microadenoma.

abnormal in all.
Out of 30 patients who underwent surgery, thirteen
patients had serum GH level of <2.5 ng/ml, four had levels
between 2.5-5 whereas 13 had elevated levels.
Postoperative OGT was done in 5 patients and no suppression of GH was there in four cases. Thus 13 had biochemical cure, 4 patients were in remission and 13 failed to
respond to surgical treatment( Table 2). The outcome in
microadenoma was better than in macroadenoma i.e., 100%
vs. 32%.
Preoperatively four patients had panhypopituitarism,
who did not recover from suppression after surgery.
Postoperatively, additional six patients (20%) had panhypopituitarism.

Discussion
Acromegaly is a slowly progressive disease characterized by disfigurement and disability.14 Mortality in
untreated acromegalics is probably two to three times that of
healthy people.1,15 The observation that this increased mortality is decreased to normal in a population of cured
acromegalics16 highlights the importance of achieving a
biochemical cure. Treatment by surgery not only offers the

Remission

Failure

4 (16%)

13 (52%)

Total
25 (100%)
5 (100%)

4 (13.3%)

13 (43.3%)

30 (100%)

Figure 3. GH levels in macroadenoma.

advantage of an immediate decline of GH levels17 but also
relieves the local pressure effects, reducing the systemic
morbidity and normalizing the mortality. Surgery thus
remains the first line treatment modality with adjuvent therapy consisting of radiotherapy and/or medical treatment.
We retrospectively analyzed the clinical features and
outcome of transsphenoidal hypophysectomy, in patients
with acromegaly. There was male preponderance i.e. 60%
whereas other studies suggested nearly equal sex distribution.18,19 We found that the mean age was lower than that
reported in other studies i.e., 35.6 years as compared to
46.320 and 5018 years.
The changes in appearance occur insidiously, so that
very often the disorder is diagnosed only when a new physician replaces the usual doctor and sees the patient for the
first time or when photographs of the patient taken over a
number of years are collected together.5 Hence there can be
a delay of 5-8 years18,19 in the diagnosis. From the charts
reviewed it was noted that the mean duration of symptoms
reported by the patients, was 3.3 ± 2.4 years (Table 1). This
comparatively short duration can either be because of more
aggressive disease but more likely this can be due to delay
on part of the patient in observing the subtle changes in the

on part of the patient in observing the subtle changes
in the features until they become very obvious.
Majority of patients had macroadenoma which is in
accordance with literature.16,18 It has been suggested that
young patients with acromegaly generally have larger and
more rapidly growing tumours at the time of diagnosis than
older patients.21 Our data also showed that macroadenoma
was seen in younger age group i.e. between 16-52 years
with median of 31 years, whereas in case of microadenoma
median age was 45 (Table 1).
The definition of cure of acromegaly has been a matter of controversy. Till 1980s, a post therapeutic GH level
<5 ng/ml was considered to be consistent with disease
cure22-24 but in the beginning of mid 1990s, a more stringent
definition of cure has been used because analyses of long
term outcomes have shown that mortality rates among treated acromegalics do not reach those of the normal population
until GH levels drop below 2.5 ng/ml.25 It was seen that
with levels less than 5 ng/ml, there was recurrence of the
disease in most of patients but with levels less than
2.5ng/ml, the long term cure rate went upto 97%.26
Accordingly using the older criteria, many patients will
experience remission of their disease rather than a cure.13
According to the consensus statement issued in
19997, the cure is said to be achieved when circulating IGFI is reduced to an age-adjusted normal range and nadir GH
after an oral glucose load is less than 1 µg/L.
In our study, 13 patients had GH level of <2.5 ng/ml
and only 5 of them underwent dynamic study with OGTT
with one patient having suppression of GH level. So there
was a biochemical cure rate of 43.3% (Table 2) which is the
same as reported by Sheaves et al26 using the strict criteria.
IGF 1 level measurement is not available in our country.
Thus random GH levels and OGTT suppression test are
only available tests to asses treatment outcome.
The study had a number of limitations. It was a retrospective analysis of the charts, most of the patients followed
up with neurosurgeons rather than endocrinologists, unavailability of IGF 1 level measurement and only few of them had
dynamic testing done to asses the cure.
The surgical outcome in microadenoma was better
than with macroadenoma i.e., 100% vs. 32% but there were
limited number of cases with microadenoma (n=5).
Generally, the microadenomas do well postoperatively than
macroadenomas.26
During selective adenomectomy, pituitary function
is generally well preserved27 and preoperative suppression
also improves as a result of surgical removal of the tumour.
Ross and Wilson showed that only nine (5.2%) of 172
patients had postoperative deterioration of pituitary function.22 We observed that preoperatively four patients had

hypopituitarism which persisted postoperatively. In the
present study postoperative hypopituitarism was seen in significant number of cases (20%).
In conclusion, the data reviewed showed that
acromegaly was seen at a much earlier age, more aggressive
disease was seen in younger age group, the outcome of surgery was comparable to other studies and postoperative
panhypopituitarism was seen in significant number of
patients. The outcome in microadenoma was better than in
macroadenoma but the number of patients seen with
microadenoma was small.

Acknowledgement
We wish to thank Mr Muhammad Islam, PGD (statistics), Research Coordinator, Department of Medicine, Aga
Khan University Hospital for his help in statistical analysis.

References
1.

Bates AS, Van't Hoff W, Jones JM, et al. An audit of outcome of treatment in
acromegaly. Q J Med1993;86:293-9.

2.

Melmed S, Ho K, Klibanski A, et al. Clinical review. 75:Recent advances in
pathogenesis, diagnosis and management of acromegaly. J Clin Endocrinol
Metab 1995;80:3395-402.

3.

Tharper K, Kovacs K, Stefaneanu L, et al. Overexpression of the growth hormone releasing hormone gene in acromegaly associated pituitary tumors: an
event associated with neoplastic progression and aggressive behavior. Am J
Pathol 1997;151:769-84.

4.

Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly. Clinical and biochemical
features in 500 patients. Medicine (Baltimore), 1994;73:233-40.

5.

Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin
North Am 1992;21:597-614.

6.

Lamberts SWJ. Acromegaly and its treatment. J Endocrinol 1997;155 (Suppl1): S49-51.

7.

Giustina A, Barkan A, Casaneuva FF, et al. Criteria for cure of acromegaly: a
consensus statement. J Clin Endocrin Metab 2000;85:526-9.

8.

Sheaves R, Jenkins P, Blackburn P, et al. Outcome of transsphenoidal surgery
for acromegaly using strict criteria for surgical cure. Clin Endocrinol 1996;
45:407-13.

9.

Ahmed S, Elsheikh M, Stratton IM, et al. Outcome of transsphenoidal surgery
for acromegaly and its relationship to surgical experience. Clin Endocrinol
1999;50:561-7.

10.

Melmed S. Acromegaly. Metabolism 1996;45(suppl 1):51-52.

11.

Fredu PU, Wardlaw SL, Post KD. Long term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly.
J Neurosurg 1998;89:353-8.

12.

Tindal GT, Oyesiku NM, Watts NB, et al. Transsphenoidal adenomectomy for
growth hormone - secreting pituitary adenomas in acromegaly: outcome
analysis and determinants of failure. J Neurosurg 1993;78:205-15.

13.

Melmed S, Jackson I, Kleinberg D, et al. Current treatment guidelines for
acromegaly. J Clin Endocrin Metab 1998;83 2646-2652.

14.

Melmed S. Acromegaly. N Engl J Med, 1990; 322:966-77.

15.

Alexander L, Appleton D, Hall R, et al. Epidemiology of acromegaly in the
Newcastle region. Clin Endocrinol 1980;12 71-9.

16.

Swearingen B, Backer FG, Katznelson L, et al. Longterm mortality after
transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin
Endocrinol Metab,1998;83 3419-26.

17.

Hardy J, Somma M. vfb Acromegaly: Surgical treatment by transsphenoidal
microsurgical removal of the pituitary adenoma. In: Tindall GT, Collins WF
(eds). Clinical Management of Pituitary Disorders. NewYork, Raven Press;
1979; p. 209.

18.

Fakuda I, Hizuka N, Murakami Y, et al. Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women's Medical University.
Intern Med 2001;40:987-92.
Ezzat S, Forester MJ, Berchtold P, et al. Acromegaly. Clinical and biochemi-

19.

19.

Ezzat S, Forester MJ, Berchtold P, et al. Acromegaly. Clinical and biochemical features in 500 patients. Medicine 1994;73:233-40.

20.

24.

Kreutzer J, Vance ML, Lopes BS, et al. Surgical management of GH secreting
pituitary adenomas: an outcome study using modern remission criteria. J Clin
Endocrin Metab 2001;86:4072-77.

Lindholm J, Giwercman B, Giwercman A, et al. Investigation criteria for
assessing the outcome of treatment in acromegaly. Clin Endocrinol
1987;27:553-62.

25.

21.

Serri O, Robert F, Comtois R, et al. Distinctive features of prolactin secretion
in acromegalic patients with hyperprolactinemia, 1987;17:429-36.

Bates AS, Van't Hoff, Jones JM, et al. Does treatment of acromegaly affect life
expectancy? Metabolism, 1995; 44( suppl 1): 1-5.

26.

22.

Ross DA, Wilson CB. Results of transsphenoidal surgery for GH-secreting
pituitary adenoma in a series of 214 patients. J Neurosurg 1988;68:854-67.

Sheaves R, Jenkin P, Blackburn P, et al. Outcome of transsphenoidal surgery
for acromegaly using strict criteria for surgical cure. Clin Endocrinol
1996;45:407-13.

23.

Laws ER, Piepgras DG, Randall RV, et al. Neurosurgical management of
acromegaly. Results in 82 patients treated between 1972 & 1977. J Neurosurg,
1979;50:454-61.

27.

Giovanelli MA, Fahlbusch R, Giani SM, et al . Surgical treatment of growth
hormone secreting microadenoma. In: Faglia G, Giovanelli MA, Macleod RM
(eds): Pituitary Microadenomas. London, Academic Press; 1980, p. 427.

